Abscopal Effect from the Low-dose Radiotherapy in Polymetastatic Cancer Patients Receiving Stereotactic Radiotherapy (KROG22-11)
Abscopal Effect from the Addition of Low-dose Radiotherapy in Polymetastatic Cancer Patients Receiving Stereotactic Radiotherapy: a Multicenter, Single-arm Clinical Study (KROG 22-11)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Jae Sik Kim, MD
- Phone Number: +82-2-709-3254
- Email: icarusky@schmc.ac.kr
Study Locations
-
-
-
Seoul, Korea, Republic of
- Recruiting
- Seoul Metropolitan Government Seoul National University Boramae Medical Center
-
Contact:
- Byoung Hyuck Kim, MD, PhD
- Phone Number: +82-2-870-1683
- Email: karlly71@hanmail.net
-
Seoul, Korea, Republic of
- Not yet recruiting
- Soonchunhyang University Seoul Hospital
-
Contact:
- Jae Sik Kim, MD
- Phone Number: +82-2-709-3254
- Email: myicarusky@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients who can provide their written informed consent
- Age ≥19 years
- Patients with histologically confirmed primary solid (irrespective of the status of the primary tumor)
- Patients with ECOG performance status 0-2
- Patients planning stereotactic body radiotherapy (three fractions) for extracranial metastases
- Based on RECIST v1.1, patients with at least one extracranial measurable lesion other than SBRT lesions
- Patients with one or more measurable lesions, which are not suitable for SBRT or palliative radiotherapy and can be considered for LDRT (bone metastasis is not indicated for LDRT)
- Patients with hematologic function suitable for radiotherapy (absolute neutrophil count ≥1,500/mm^3, hemoglobin ≥9 g/dL, platelet count ≥100,000/mm^3)
- Patients with a life expectancy of 6 months or more according to the researcher's judgment
Exclusion Criteria:
- Patients participating in other clinical studies that may affect the efficacy/safety of this clinical study
- Patients with brain metastasis
- Patients planning SBRT for all measurable lesions due to oligometastasis
- Patients with a history of radiotherapy for extracranial metastases within 3 months of the enrollment
- Patients unable to cooperate with stereotactic body radiotherapy
- Patients who are pregnant or planning to
- Patients with advanced or multiple malignancies requiring aggressive treatment (excluding skin cancers other than melanoma or intraepithelial cancer)
- Patients who have received systemic steroid therapy or immunosuppressive therapy within 2 weeks of enrollment - Patients with an (e.g. allergic disease, radiation pneumonitis, etc.) (The use of steroids for preventive purposes is allowed (e.g., to prevent vomiting during chemotherapy)) active autoimmune disease requiring systemic treatment within the past 2 years, evidence of clinically severe autoimmune disease, or syndrome requiring systemic steroid or immunosuppressive therapy (Patients who need intermittent use of bronchodilators, inhaled steroids, or topical steroid injections, hypothyroid patients on stable hormone replacement therapy, type 1 diabetes patients, or patients recovering from childhood asthma/atopic dermatitis are permitted)
- Patients with active infection requiring systemic treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: SBRT + LDRT
|
Stereotactic body radiotherapy (SBRT) and low-dose radiotherapy (LDRT) are administered concurrently.
SBRT is administered three times, at intervals of 1-2 days, and patients are treated with LDRT along with SBRT.
LDRT is planned to irradiate EQD2 6 Gy considering the scattered dose caused by SBRT.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Abscopal effect rate of low-dose radiotherapy lesions
Time Frame: 3 months after completion of radiotherapy
|
The proportion of patients with an abscopal response of low-dose radiotherapy lesions assessed by RECIST v1.1
|
3 months after completion of radiotherapy
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Abscopal effect rate of low-dose radiotherapy lesions
Time Frame: 1, 6, and 12 months after completion of radiotherapy
|
The proportion of patients with an abscopal response of low-dose radiotherapy lesions assessed by RECIST v1.1
|
1, 6, and 12 months after completion of radiotherapy
|
|
Overall response rate
Time Frame: 1, 3, 6, and 12 months after completion of radiotherapy
|
The proportion of patients showing complete or partial response of metastatic lesions
|
1, 3, 6, and 12 months after completion of radiotherapy
|
|
Progression-free survival rate
Time Frame: 12 months after completion of radiotherapy
|
From the date of enrollment to the date of progression or death assessed by RECIST v1.1
|
12 months after completion of radiotherapy
|
|
Overall survival rate
Time Frame: 12 months after completion of radiotherapy
|
From the date of enrollment to the date of death or last follow-up assessed by RECIST v1.1
|
12 months after completion of radiotherapy
|
|
Adverse event
Time Frame: 12 months after completion of radiotherapy
|
The proportion of patients with treatment-related adverse events as assessed by CTCAE v5.0
|
12 months after completion of radiotherapy
|
|
Immune cell subsets of peripheral blood and tissue samples
Time Frame: 1 and 3 months after completion of radiotherapy
|
Number of immune cell count
|
1 and 3 months after completion of radiotherapy
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Ah Ram Chang, MD, PhD, Soonchunhayng Universtiy Seoul Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SCHUH 2022-10-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.